A Study for Tysabri Participant Preference

The primary objective of this study is to collect, evaluate and compare data on participant preference between subcutaneous (SC) and intravenous (IV) natalizumab. The secondary objectives of this stud...

Lead sponsor: Biogen•40 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

TERMINATEDPhase 3

Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab

NCT02881567 · Relapsing-Remitting Multiple Sclerosis (RRMS)

WITHDRAWNPhase 4

Brimonidine Tartrate for the Treatment of Injection Related Erythema

NCT02568111 · Relapsing-Remitting Multiple Sclerosis (RRMS)

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 17, 2024Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment318

Start dateOct 2021

Last updatedMay 17, 2024

Condition

Relapsing-Remitting Multiple Sclerosis (RRMS)

Locations shown

Neurozentrum am Königsplatz Augsburg; Dres. Müller und Schmid

Augsburg

Praxis Dr. Schöll

Bad Homburg

Caritas Krankenhaus Bad Mergentheim

Bad Mergentheim

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 17, 2024Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions